NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Phase 2

Completed

Conditions: Kidney Transplant

Interventions: Biological: Infliximab
Drug: Methylprednisolone
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Biological: Thymoglobulin®
Drug: Acetaminophen
Biological: Placebo for Infliximab
Drug: Loratadine
Drug: Prednisone
Drug: Diphenhydramine

First Posted Date: 2015-07-13

Last Posted Date: 2022-08-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 290

Registration Number: NCT02495077

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 12 locations

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Phase 4

Terminated

Conditions: Influenza Immunisation
Influenza

Interventions: Biological: Influenza Virus Vaccine Inactivated

First Posted Date: 2015-06-30

Last Posted Date: 2023-10-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT02485639

Locations: 🇺🇸
Emory Clinic - Winship Cancer Institute, Atlanta, Georgia, United States

Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Upper Respiratory Tract Infection

Interventions: Biological: RSV A2

First Posted Date: 2015-06-29

Last Posted Date: 2025-04-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT02484417

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Ruxolitinib

First Posted Date: 2015-06-19

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT02475655

Locations: 🇺🇸
Weill Cornell Chelsea CRS, New York, New York, United States
🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States

and more 11 locations

Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

Phase 1

Completed

Conditions: Liver Transplant Recipient
Living Donor (of the Respective Liver Transplant Recipient)

Interventions: Biological: darTregs
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Immunosuppression (IS) Withdrawal
Procedure: Study Mandated Procedures

First Posted Date: 2015-06-17

Last Posted Date: 2021-02-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT02474199

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
Northwestern University Comprehensive Transplant Ctr, Chicago, Illinois, United States

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

Phase 1

Completed

Conditions: Gastroenteritis Norovirus

Interventions: Biological: Norovirus GII.2 Challenge
Other: Placebo

First Posted Date: 2015-06-16

Last Posted Date: 2018-12-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 44

Registration Number: NCT02473224

Locations: 🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States

Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates

Recruiting

Conditions: Malaria

First Posted Date: 2015-06-15

Last Posted Date: 2025-04-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7476

Registration Number: NCT02471378

Locations: 🇲🇱
Ouelessebougou Clinical Research Center, Bamako, Mali

VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption

Phase 1

Completed

Conditions: HIV

Interventions: Biological: VRC-HIVMAB060-00-AB (VRC01)

First Posted Date: 2015-06-15

Last Posted Date: 2017-10-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT02471326

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: VRC01

First Posted Date: 2015-06-04

Last Posted Date: 2021-10-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 14

Registration Number: NCT02463227

Locations: 🇺🇸
Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States
🇺🇸
Alabama CRS, Birmingham, Alabama, United States

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

Phase 1

Completed

Conditions: Cytomegalovirus Infection

Interventions: Drug: MBX400
Other: Placebo

First Posted Date: 2015-05-27

Last Posted Date: 2017-12-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT02454699

Locations: 🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy